Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy

Journal of Viral Hepatitis

Volumn 23, Issue 12, 2016, Pages 994-1002

  Knop, V ^a   Hoppe, D ^a   Welzel, T ^a   Vermehren, J ^a   Herrmann, E ^b   Vermehren, A ^a   Friedrich Rust, M ^a   Sarrazin, C ^a   Zeuzem, S ^a   Welker, M W ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

cirrhosis; DAA; elastography; HCV; portal hypertension

Indexed keywords

DACLATASVIR; DASABUVIR; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT;

ACOUSTIC RADIATION FORCE IMPULSE IMAGING; ADULT; AGED; ARTICLE; BIOCHEMISTRY; DISEASE ASSOCIATION; FEMALE; HEMATOLOGICAL PARAMETERS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; PORTAL HYPERTENSION; PRIORITY JOURNAL; SPLEEN STIFFNESS; TRANSIENT ELASTOGRAPHY; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY; COMPLICATION; HEPATITIS C, CHRONIC; LIVER; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; SPLEEN; SUSTAINED VIROLOGIC RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; HYPERTENSION, PORTAL; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SPLEEN; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

EID: 84995632443     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12578     Document Type: Article

References (49)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558–567.
2. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553–562.
3. Scheel TKH, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med. 2013;19:837–849.
4. Curry MP, O`Leary JG, Bzowej N, et al. Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618–2628.
5. Manns M, Samuel D, Gane EJ, et al. Ledipasvir and Sofosbuvir plus Ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomized, phase 2 trial. Lancet Infect Dis. 2016;16:685–697. Epub ahead of print
6. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and Sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015;149:649–659.
7. Foster GR, Irving WL, Cheung MCM, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64:1224–1231.
8. Pellicelli AM, Montalbano M, Lionetti R, et al. Sofosbuvir plus Daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity, but no clinical benefit if treatment is given late. Dig Liver Dis. 2014;46:923–927.
9. Coilly A, Pageaux G, Houssel-Debry P, et al. Improving liver function and delisting of patients awaiting liver transplantation for HCV cirrhosis: do we ask too much to DAA? Hepatology 2015;51S:275A.
10. Lee YA, Friedman SL. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C. Antiviral Res. 2014;107:23–30.
11. D'Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006;131:1611–1624.
12. Iacobellis A, Siciliano M, Perri F, et al. Peginterferon alfa-2b and Ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol. 2007;46:206–212.
13. Van der Meer AJ, Maan R, Veldt BJ, et al. Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. J Gastroenterol Hepatol. 2016;31:1168–1176. Epub ahead of print
14. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009;49:729–738.
15. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132:517–527.
16. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303–1313.
17. Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with Sofosbuvir and Ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 2016;63:1493–1505.
18. Fontana RJ, Brown RS Jr, Moreno-Zamora A, et al. Daclatasvir combined with Sofosbuvir or Simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transpl. 2016;22:446–458.
19. Everson GT, Galleja JL, McCaughan G, et al. Effect of long term viral suppression with Sofosbuvir and Ribavirin on hepatic venous pressure gradient in HCV-infected patients with cirrhosis and portal hypertension. J Hepatol. 2015;62(Suppl. 2):S269–S270.
20. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 2009;49:1077–1044.
21. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008;134:960–974.
22. Talwalker JA, Kurtz DM, Schoenleber SJ, West CP, Montori VM. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2007;5:1214–1220.
23. Stebbing J, Farouk L, Panos G, et al. A meta-analysis of transient elastography for the detection of hepatic fibrosis. J Clin Gastroenterol. 2010;44:214–219.
24. Piscaglia F, Salvatore V, Di Donato R, et al. Accuracy of virtual touch acoustic radiation force impulse (ARFI) imaging for the diagnosis of cirrhosis during liver ultrasonography. Ultraschall Med. 2011;32:167–175.
25. Friedrich-Rust M, Nierhoff J, Lupsor M, et al. Performance of acoustic radiation force impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat. 2012;19:212–219.
26. Rosenberg WM, Voelker M, Thiel R, et al. European Liver Fibrosis Group. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127:1704–1713.
27. Poynard T, Imbert-Bismut F, Ratziu V, et al. GERMED cyt04 group. Biochemical markers of liver fibrosis in patients infected by Hepatitis C virus: longitudinal validation in randomized trial. J Viral Hepat. 2002;9:128–133.
28. Guha IN, Parkers J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008;47:455–460.
29. Morikawa H, Kawada N. Non-invasive diagnosis of liver fibrosis. Clin J Gastroenterol. 2011;4:283–291.
30. Bota S, Herkner H, Sporea I, et al. Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. Liver Int. 2013;33:1138–1147.
31. Goldschmidt I, Brauch C, Poynard T, Baumann U. Spleen stiffness measurement by transient elastography to diagnose portal hypertension in children. J Pediatr Gastroenterol Nutr. 2014;59:197–203.
32. Colecchia A, Montrone L, Scaioli E, et al. Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis. Gastroenterology 2012;143:646–654.
33. Mori K, Arai H, Abe T, et al. Spleen stiffness correlates with the presence of ascites, but not esophageal varices in chronic hepatitis C patients. BioMed Res Int. 2013; doi:10.1155/2013/857862.
34. Attia D, Schoenemeier B, Rodt T, et al. Evaluation of liver and spleen stiffness with acoustic radiation force impulse quantification elastography for diagnosing clinically significant portal hypertension. Ultraschall Med. 2015;36:603–610.
35. Wai CT, Greenson JK, Fontana RJ, et al. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518–526.
36. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2011;33:464–470.
37. Child CG, Turcotte JG. Surgery and Portal Hypertension. Philadelphia: Saunders; 1964:50–64.
38. Welzel TM, Petersen J, Herzer K, et al. Daclatasvir plus Sofosbuvir with or without Ribavirin for treatment of chronic HCV infection in patients with advanced liver disease: results of a European compassionate use program. J Hepatol 2016;64(suppl.2):S825.
39. Welker MW, Luhne S, Lange CM, et al. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined Ribavirin/Sofosbuvir treatment. J Hepatol. 2016;64:790–799.
40. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29:1705–1713.
41. Mederacke I, Wursthorn K, Kirschner J, et al. Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver Liver Int. 2009;29:1500–1506.
42. Castera L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010;51:828–835.
43. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48:835–847.
44. Nightingale K, Soo MS, Nightingale R, Trahey G. Acoustic radiation force impulse imaging: in vivo demonstration of clinical feasibility. Ultrasound Med Biol. 2002;28:227–235.
45. Karlas T, Lindner F, Troltzsch M, Keim V. Assessment of spleen stiffness using acoustic radiation force impulse imaging (ARFI): definition of examination standards and impact of breathing maneuvers. Ultraschall Med. 2014;35:38–43.
46. Bruno S, Boccaccio V, Russo ML, et al. Is the benefit of treating patients with cirrhosis proven? Liver Int 2016;36(Suppl.S1):21–27.
47. D`Ambrosio R, Aghemo A, Fraquelli M, et al. The diagnostic accuracy of FibroScan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. J Hepatol. 2013;59:251–256.
48. Fraquelli M, Rigamonti C, Casazza G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007;56:968–973.
49. Bota S, Sporea I, Peck-Radosavljevic M, et al. The influence of aminotransferase levels on liver stiffness assessed by acoustic radiation force impulse elastography: a retrospective multicentre study. Dig Liver Dis. 2013;45:762–768.